Form 424B5 Biohaven Pharmaceutical
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stock futures fall as fading Iran peace prospects drive up oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Canaccord Genuity Sees Buying Opportunity in Biohaven Pharmaceutical (BHVN)
June 18, 2019 10:48 AM EDTCanaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating and $89.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN), saying while the sequence of events is very unfortunate the significant downside presents an opportunity.
"The curious mix of events - a... More
